Discovery of N-[(4R)-6-(4-Chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a Novel Cannabinoid-1 Receptor (CB1R) Inverse Agonist for the Treatment of Obesity

被引:18
作者
Yan, Lin [1 ]
Huo, Pei [1 ]
Debenham, John S. [1 ]
Madsen-Duggan, Christina B. [1 ]
Lao, Julie [2 ]
Chen, Richard Z. [2 ]
Xiao, Jing Chen [2 ]
Shen, Chun-Pyn [2 ]
Stribling, D. Sloan [3 ]
Shearman, Lauren P. [3 ]
Strack, Alison M. [3 ]
Tsou, Nancy [5 ]
Ball, Richard G. [5 ]
Wang, Junying [4 ]
Tong, Xinchun [4 ]
Bateman, Thomas J. [4 ]
Reddy, Vijay B. G. [4 ]
Fong, Tung M. [2 ]
Hale, Jeffrey J. [1 ]
机构
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA
[3] Merck Res Labs, Dept Pharmacol, Rahway, NJ 07065 USA
[4] Merck Res Labs, Dept Drug Metab & Pharmacokinet, Rahway, NJ 07065 USA
[5] Merck Res Labs, Dept Pharmaceut Res & Dev, Rahway, NJ 07065 USA
关键词
PHARMACOLOGICAL-PROPERTIES; TARANABANT; MK-0364; POTENT;
D O I
10.1021/jm100023j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This paper describes the discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596, 12c) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity. Structure activity relationship (SAR) studies of lead compound 3, which had off-target hERG (human ether-a-go-go related gene) inhibition activity, led to the identification of several compounds that not only had attenuated hERG inhibition activity but also were subject to glucuronidation in vitro providing the potential for multiple metabolic clearance pathways. Among them, pyrazole 12c was found to be a highly selective CB1R inverse agonist that reduced body weight and food intake in a DIO (diet-induced obese) rat model through a CB1R-mediated mechanism. Although 12c was a substrate of P-glycoprotein (P-gp) transporter, its high in vivo efficacy in rodents, good pharmacokinetic properties in preclinical species, good safety margins, and its potential for a balanced metabolism profile in man allowed for the further evaluation of this compound in the clinic.
引用
收藏
页码:4028 / 4037
页数:10
相关论文
共 36 条
[1]   Multiple-dose pharmacokinetics, pharmacodynamics, and safety of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, in healthy male volunteers [J].
Addy, Carol ;
Rothenberg, Paul ;
Li, Susie ;
Majumdar, Anup ;
Agrawal, Nancy ;
Li, Hankun ;
Zhong, Ling ;
Yuan, Finyu ;
Maes, Andrea ;
Dunbar, Stephanie ;
Cote, Losee ;
Rosko, Kim ;
Van Dyck, Kristien ;
De Lepeleire, Inge ;
de Hoon, Jan ;
Van Hecken, Anne ;
Depre, Marleen ;
Knops, Annemie ;
Gottesdiener, Keith ;
Stoch, Aubrey ;
Wagner, John .
JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (06) :734-744
[2]   A critical review of the cannabinoid receptor as a drug target for obesity management [J].
Akbas, F. ;
Gasteyger, C. ;
Sjodin, A. ;
Astrup, A. ;
Larsen, T. M. .
OBESITY REVIEWS, 2009, 10 (01) :58-67
[3]   Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists [J].
Armstrong, Helen E. ;
Galka, Amy ;
Lin, Linus S. ;
Lanza, Thomas J., Jr. ;
Jewell, James P. ;
Shah, Shrenik K. ;
Guthikonda, Ravi ;
Truong, Quang ;
Chang, Linda L. ;
Quaker, Grace ;
Colandrea, Vincent J. ;
Tong, Xinchun ;
Wang, Junying ;
Xu, Sherry ;
Fong, Tung M. ;
Shen, Chun-Pyn ;
Lao, Julie ;
Chen, Jing ;
Shearman, Lauren P. ;
Stribling, D. Sloan ;
Rosko, Kimberly ;
Strack, Alison ;
Ha, Sookhee ;
Van der Ploeg, Lex ;
Goulet, Mark T. ;
Hagmann, William K. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (08) :2184-2187
[4]   Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor [J].
Chen, Richard Z. ;
Frassetto, Andrea ;
Lao, Julie Z. ;
Huang, Ruey-Ruey C. ;
Xiao, Jing C. ;
Clements, Matthew J. ;
Walsh, Thomas F. ;
Hale, Jeffrey J. ;
Wang, Junying ;
Tong, Xinchun ;
Fong, Tung M. .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 584 (2-3) :338-342
[5]   Overview of human obesity and central mechanisms regulating energy homeostasis [J].
Crowley, Vivion E. F. .
ANNALS OF CLINICAL BIOCHEMISTRY, 2008, 45 :245-255
[6]   Furo[2,3-b]pyridine-based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation. Part 1 [J].
Debenham, John S. ;
Madsen-Duggan, Christina B. ;
Toupence, Richard B. ;
Walsh, Thomas F. ;
Wang, Junying ;
Tong, Xinchun ;
Kumar, Sanjeev ;
Lao, Julie ;
Fong, Tung M. ;
Xiao, Jing Chen ;
Huang, Cathy R-R. C. ;
Shen, Chun-Pyn ;
Feng, Yue ;
Marsh, Donald J. ;
Stribling, D. Sloan ;
Shearman, Lauren P. ;
Strack, Alison M. ;
Goulet, Mark T. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (04) :1448-1452
[7]   Pyridopyrimidine based cannabinoid-1 receptor inverse agonists: Synthesis and biological evaluation [J].
Debenham, John S. ;
Madsen-Duggan, Christina B. ;
Wang, Junying ;
Tong, Xinchun ;
Lao, Julie ;
Fong, Tung M. ;
Schaeffer, Marie-Therese ;
Xiao, Jing Chen ;
Huang, Cathy C. R. -R. ;
Shen, Chun-Pyn ;
Stribling, D. Sloan ;
Shearman, Lauren P. ;
Strack, Alison M. ;
MacIntyre, D. Euan ;
Hale, Jeffrey J. ;
Walsh, Thomas F. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (09) :2591-2594
[8]   Synthesis of functionalized 1,8-naphthyridinones and their evaluation as novel, orally active CB1 receptor inverse agonists [J].
Debenham, JS ;
Madsen-Duggan, CB ;
Walsh, TF ;
Wang, JY ;
Tong, XC ;
Doss, GA ;
Lao, J ;
Fong, TM ;
Schaeffer, MT ;
Xiao, JC ;
Huang, CRRC ;
Shen, CP ;
Feng, Y ;
Marsh, DJ ;
Stribling, DS ;
Shearman, LP ;
Strack, AM ;
MacIntyre, DE ;
Van der Ploeg, LHT ;
Goulet, MT .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (03) :681-685
[9]  
DEBENHAM JS, 2008, Patent No. 2008094473
[10]   CB1 antagonists for obesity-what lessons have we learned from rimonabant? [J].
Di Marzo, Vincenzo ;
Despres, Jean-Pierre .
NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (11) :633-638